PUBLICATIONS  



 

Papers, Patents 

  1. Neyts J, Puerstinger G, De Clercq E. Preparation of imidazopyridines as viral inhibitors. WO 2004005286, A2 20040115.
  2. Hofmann J, Heinisch G, Easmon J, Puerstinger G, Fiebig, HH. Preparation of heterocyclic hydrazones for use as anti-cancer agents active against multidrug-resistant cancer cells. WO 2001094340, A1 20011213.
  3. Easmon J, Puerstinger G, Roth T, Fiebig HH, Jenny M, Jaeger W, Heinisch G, Hofmann J. 2- Benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: a novel class of antitumor agents. Int. J. Cancer 94(1) (2001) 89-96.
  4. Easmon J, Puerstinger G, Heinisch G, Roth T, Fiebig HH, Holzer W, Jaeger W, Jenny M, Hofmann J. Synthesis, Cytotoxicity, and Antitumor Activity of Copper(II) and Iron(II) Complexes of 4N-Azabicyclo[3.2.2]nonane Thiosemicarbazones Derived from Acyl Diazines. J. Med. Chem. 44(13) (2001) 2164-2171.
  5. Jenny M, Easmon J, Puerstinger G, Heinisch G, Hofmann J. Screening of new potential ribonucleotide reductase inhibitors in tissue culture. Contributions to Oncology 54 (Relevance of Tumor Models for Anticancer Drug Development) (1999) 409-417.
  6. Hall IH, Peaty NJ, Henry JR, Easmon J, Heinisch G, Purstinger G. Investigations on the mechanism of action of the novel antitumor agents 2-benzothiazolyl, 2-benzoxazolyl, and 2- benzimidazolyl hydrazones derived from 2-acetylpyridine. Arch. Pharm. 332(4) (1999) 115-123.
  7. Stanetty P, Puerstinger G. Synthesis of aza analogs of the herbicide Sindone B. Monatsh. Chemie 130(3) (1999) 441-450.
  8. Jenny M, Easmon J, P�rstinger G, Heinisch G, Hofmann J. Screening of New Potential Ribonucleotide Reductase Inhibitors in Tissue Culture. Relevance of Tumor Models for Anticancer Drug Development (1999).
  9. Stanetty P, Puerstinger G. Monatsh. Chem. 130(3), 441-450 (1999).
  10. Easmon J, Heinisch G, P�rstinger, Magreiter G, Hofmann J. Benzothiazolyl, Benzoxazolyl and Benzimidazolyl Hydrazones Derived from 2-Acylpyridines: Synthesis and Antitumor Evaluation. Proc. Amer. Assoc. Cancer Res. 40 (1999) 395.
  11. Subramanian SV, Adunyah SE, Easmon J, Heinisch G, P�rstinger G. Induction of Tyrosine Phosphorylation by Thiazolyl and Benzothiazolyl Hydrazone novel Anticancer Agents in Human K562 and U937 Leukemia Cells. Proc. Amer. Assoc. Cancer Res. 39 (1998) 66.
  12. Easmon J, Heinisch G, Hofmann J, Langer T, Grunicke HH, �sterreicher J, P�rstinger G. Synthesis and Antitumoral Evaluation of Substituted 2-Benzoylpyridine-2-Pyridylhydrazones as Potential Ribonucleotide Reductase Inhibitors. Proc. Amer. Assoc. Cancer Res. 38 (1997) 102.
  13. Easmon J, Heinisch G, Hofmann J, P�rstinger G. Synthesis and evaluation of the cytotoxicity of thiosemicarbazones derived from acetyldiazines and metal complexes thereof. Proc. Amer. Assoc. Cancer Res. 37 (1996) 395.
  14. Hall IH, Peaty, NJ, Henry JR, Easmon J, Heinisch G, P�rstinger G. Investigations on the Mechanism of Action of the Novel Antitumor Agents 2-Benzothiazilyl, 2-Benzoxozolyl, and 2-benzimidazolyl hydrazones Derived from 2-Acetylpyridine Arch. Pharm.-Pharm. Med. Chem. 332 (1999) 113-123.
  15. Heinisch G, Matuszczak B, P�rstinger G, Rakowitz D. Diazine�Substituted tert.-Butylureas and tert.-Butylthioureas and a Convenient Access to the Related Carbodiimides J. Heterocycl. Chem. 32 (1995) 13-16.
  16. Easmon J, Grunicke HH, Heinisch G, Hofmann J, Langer T, P�rstinger G. Azinyl and Diazinyl Hydrazones Derived From a-(N)-Heteroaryl Ketones: Synthesis, Antiproliferative Activity, and QSAR J. Med. Chem. 40 (1997) 4420-4425.
  17. Easmon J, Heinisch G, Hofmann J, Langer T, Fink J, Grunicke HH, P�rstinger G. Thiazoyl and benzothiazoyl hydrazones derived from a-(N)-acetylpyridines and es: Synthesis, antiproliferative activity, and CoMFA studies Eur. J. Med. Chem. 32 (1997) 397-408.